Current clinical evidence is insufficient to determine whether insulin-like growth factor-1 (IGF-1) treatment improves outcomes for premature infants at risk of retinopathy of prematurity (ROP). While IGF-1 is essential for normal retinal vascular development, ongoing research has yet to establish its efficacy or safety profile in neonatal care, leaving standard clinical practices unchanged.
What is the Role of IGF-1 in Preterm Infants?
Insulin-like growth factor-1 is a naturally occurring protein that facilitates the growth of blood vessels in the retina during gestation. According to the Pediatric Research journal, infants born significantly before term often experience a rapid decline in circulating IGF-1 levels. This deficiency is hypothesized to contribute to the abnormal vascular growth characteristic of ROP, a condition that can lead to vision impairment or blindness in extremely low birth weight infants.
Current Treatment Standards for ROP
Because pharmacological interventions like IGF-1 supplementation remain experimental, neonatologists currently rely on established methods to manage ROP. The American Academy of Ophthalmology notes that standard treatment involves either laser photocoagulation—which destroys the peripheral retina to reduce the stimulus for abnormal vessel growth—or anti-VEGF injections. These medications are injected directly into the eye to temporarily inhibit the growth of pathological vessels. These procedures are performed only when the disease reaches a threshold that threatens the child’s long-term vision.
Evaluating the Evidence for IGF-1 Supplementation
Recent systematic reviews, including data available through The Cochrane Library, indicate that clinical trials investigating IGF-1 in the neonatal intensive care unit (NICU) have been limited in scope. Studies typically involve small sample sizes, which restricts the ability of researchers to detect meaningful benefits or identify rare but serious side effects.
Current research limitations include:
- Small Participant Pools: Existing trials have lacked the power to confirm definitive clinical outcomes.
- Methodological Variability: Differences in study design and administration methods make it difficult to compare results across clinical settings.
- Long-term Uncertainty: There is a lack of robust, long-term data tracking neurodevelopmental and physiological outcomes beyond early childhood.
Why Future Research Remains Critical
The primary challenge for researchers is determining if systemic IGF-1 replacement can safely mimic the intrauterine environment without causing unintended consequences. Because IGF-1 influences growth and development throughout the body, researchers must ensure that supplementation does not adversely affect other organs, such as the lungs or the brain.
As of March 2025, the medical community maintains that while the biological rationale for investigating IGF-1 is sound, it is not currently a standard therapy. Parents of premature infants are encouraged to consult their neonatologists regarding the most effective, evidence-based management strategies for ROP, which remain focused on regular ophthalmological screening and established surgical or anti-VEGF interventions.
Related reading